The greatest obstacle to clinical application of cancer gene therapy is lack of effective delivery tools. Gene delivery vehicles must protect against degradation, avoid immunogenic effects and prevent off target delivery which can cause harmful side effects. PEGylated liposomes have greatly improved tumor localization of small molecule drugs and are a promising tool for nucleic acid delivery as the polyethylene glycol (PEG) coating protects against immune recognition and blood clearance. In this study, small interfering RNA (siRNA) was fully encapsulated within E6 and E7 bind to tumor suppressor proteins p53 and pRb, marking them for degradation or blocking their binding sites, thereby preventing apoptosis and driving cellular proliferation. 6, 7 With the knowledge of the genetic mechanism of this oncovirus, several siRNA sequences targeting the gene sequences that encode the E6 and E7 proteins have been developed, demonstrating rescue of the p53 and pRb
| I N T R O D U C T I O N
E6 and E7 bind to tumor suppressor proteins p53 and pRb, marking them for degradation or blocking their binding sites, thereby preventing apoptosis and driving cellular proliferation. 6, 7 With the knowledge of the genetic mechanism of this oncovirus, several siRNA sequences targeting the gene sequences that encode the E6 and E7 proteins have been developed, demonstrating rescue of the p53 and pRb tumor suppression pathways, resulting in cell cycle arrest and apoptosis in HPV-infected cancer cells both in vitro and in vivo. [8] [9] [10] [11] [12] In order for the potential of clinical gene therapy to be realized, several key obstacles to efficient in vivo delivery need to be overcome.
For successful transfection and therapy to occur, siRNA must be internalized into the cells and released into the cytosol to mediate gene silencing.
While traversing the blood stream to reach the target tissue, siRNA must avoid degradation by nucleases, recognition by the immune system, and renal clearance. Several technologies have been developed to address each of these barriers to siRNA delivery, including chemical modification, nanoparticle complexation, and addition of targeting moieties. [1] [2] [3] [4] [5] 13 In this study, we developed cancer gene therapy delivery vehicles composed of targeted PEGylated liposomes encapsulating siRNA. PEGylated liposomes are hollow, spherical phospholipid nanoparticles functionalized with a layer of PEG which have seen clinical success for the intravenous (IV) delivery of chemotherapeutic agents. [14] [15] [16] PEGylation has been shown to increase blood circulation, minimize immunogenicity and increase tumor accumulation of IV delivered liposomes. [14] [15] [16] PEGylated liposomes present a potential solution to the toxicities observed from traditional cationic siRNA transfection agents such as PEI and 1,2-dioleoyl-3-trimethylammonium-propane. [17] [18] [19] Liposomes functionalized with ligands designed to bind to upregulated surface receptors can enhance cellular association and internalization into cancer cells. The a 6 b 4 integrins are upregulated surface receptors associated with metastatic behavior in several cancer types, including cervical cancer. [20] [21] [22] The AG86 peptide was identified as an a 6 integrin binding ligand, 23 and was investigated here for specificity for the a 6 b 4 integrin and for targeting to
HeLa cervical cancer cells. PEI complexation with nucleic acids alone has been shown to aid in endosomal escape through the proton sponge effect, whereby the high buffering capacity of PEI can cause osmotic swelling and rupture of intracellular organelles. 24 Figure S1A ). The presence of the free peptide decreased liposome binding by 98%, confirming AG86-mediated binding. The initial discovery of the AG86 peptide demonstrated specific interaction with the a 6 integrin. 23 The presence of a 6 antibodies disrupted 40% of cellular adhesion to AG86 peptide coated surfaces. 23 The a 6 integrin is known to dimerize with either the b 1 or the b 4 integrin, 32 and while blocking with a b 1 specific antibody demonstrated that AG86 binding is not specific for the a 6 b 1 heterodimer, binding to the b 4 integrin was not explored. 23 We therefore investigated the binding interactions of the AG86 peptide using antibody blocking of the AG86-functionalized PEGylated liposomes to cells (Supporting Information Figure S1B ). In the presence of anti-a 6 and anti-b 4 integrin antibodies, liposome binding is decreased by 66% and 86%, respectively, verifying the a 6 b 4
integrin as the binding target of the AG86 peptide. 
| Characterization of siRNA/PEI complexes
Before encapsulation in targeted liposomes, anionic siRNA was complexed with the cationic polymer PEI to form nanoparticles. siRNA was complexed at several different nitrogen:phosphate ratios (N:P) to investigate the effect of N:P ratio on particle size, charge, liposomal encapsulation yield and transfection efficiency. None of the particle sizes are significantly different between different N:P ratios ( Figure 3A) . 33 Representative histograms for each N:P ratio are included in Supporting Information Figure S2 . As N:P ratio was increased from 2 to 8 and more positively charged polymer was added during complexation, the zeta potential increased from 211 to 13 mV ( Figure 3B ). The larger standard error of the average particle size for siRNA/PEI complexes at N:P 5 4 is indicative of the higher size polydispersity observed from these complexes, as is commonly seen at N:P ratios that produce particles approaching a neutral charge or at the transition from negative to positive zeta potential associated with increasing N:P. DNA/PEI saturation between N:P of 2-3 using branched PEI of similar size, 34, 37, 38 and between 1 and 2.5 for siRNA/PEI. 39 In order to better observe the transition from free to fully complexed siRNA, titrations were also performed spanning N:P ratios of 0-2 ( Figure 4B,D) . A "one set of sites" model was used to calculate binding affinity (K 5 3.1 3 40 and PEI (0.25-0.35 nm). 41 Normalizing to the charge ratio, it is reasonable to expect the interaction of siRNA and PEI to resemble the interaction of DNA with PEI. The binding of siRNA and PEI in distilled water was characterized using similar thermodynamic parameters in the literature, however an n of 2.26 was identified, requiring more PEI molecules for condensation of 1 siRNA molecule. 39 This discrepancy could be caused by differing buffer conditions. 40 In Figure 4A ,B, large endothermic (positive) peaks are observed at the transition between free and complexed siRNA, and this has been attributed to an endothermic reorganization of saturated siRNA:PEI complexes into less siRNA-dense particles. Figure 5 ). 27 Encapsulation of siRNA in neutral lipid delivery systems is historically limited by low entrapment efficiency. 42 However, targeted PEGylated liposomes encapsulating siRNA complexed to PEI achieved yields of up to 60% as shown in Figure 5 . or uncomplexed siRNA (N:P 5 0) were delivered to HeLa cells and cell viability was assayed 24 hr later. As Figure 9 shows, the nanoparticles with the complexed siRNA decreased cell proliferation by 30%, while those encapsulating the uncomplexed siRNA had no effect on cell proliferation. 2.5 nM siRNA delivered using targeted PEGylated liposomes achieved 68% mRNA silencing, as shown in Figure 6 , however protein expression and subsequent phenotypic effects are not quantitatively predicted by mRNA expression and may account for the observed 30% cell toxicity. 43, 44 Our results are in agreement with previous findings where it was shown that silencing of the HPV-E7 gene using RNAi promoted 80-90% mRNA silencing and resulted in 40-60% inhibition of cell proliferation at early time points. 12, 45 Therefore, continued doses of siRNA may be necessary to achieve more potent cytotoxicity effects. The cytotoxicity from the individual components of the targeted PEGylated liposomes encapsulating siRNA/PEI was also investigated. Empty targeted PEGylated liposomes and siRNA/PEI complexes of a non-specific sequence were delivered to the HeLa cells either free in solution or encapsulated in the targeted liposomes. As Supporting Information Figure S4 shows, none of the isolated components exhibited significant cytotoxicity compared to the untreated control, thus concluding that the toxicity observed in Figure 9 was the result of transfection of the si18E7-674 siRNA sequence.
| Cell apoptosis induced by different formulations
The oncogenic behavior exhibited by the E7 viral oncogene results from its ability to bind pRb, a tumor suppressor protein that participates in apoptosis and cell cycle regulation. 8, 12, 46 An apoptosis assay was therefore performed to investigate the role of apoptosis in the cytotoxicity observed from delivery of E7-specific siRNA encapsulated within tar- osomes. These data thus validate the cell viability results of Figure 9 and Supporting Information Figure S4 . The results also highlight our approach of using AG86-functionalized liposomes that bind to a 6 b 4 -expressing HeLa cells, along with the si18E7-674 that is shown to be specific for the HPV-18 containing HeLa cells, as the formulation had no effect on the HPV-negative C33A cells. Furthermore, the lack of apoptotic signal from the delivery of targeted liposomes that were either empty or loaded with a complexed control siRNA demonstrates the safety of our delivery system itself. cytes. 52 Interestingly, surface pKa of a particular lipidoid was a critical parameter for predicting transfection efficiency for a lipidoid nanoparticle. 52 The SNALPs are a well-studied non-targeted lipid based delivery vehicle which has seen great success in preclinical studies. In one study, SNALPs were used to silence polo-like kinase 1 in tumors while abrogating activation of innate immune response and reducing tumor size by 75%. 53 Transferrin targeted cyclodextrin particles have also successfully delivered siRNA to tumors in vivo, and an accumulation/function study again revealed similar tissue accumulation for targeted and non-targeted nanoparticles, but enhanced transfection associated with targeting. 54 Preclinical results from SNALP and cyclodextran nanoparticle development motivated clinical trials for oncogene silencing and cancer treatment. 49 With these advances, many biodistribution challenges have been addressed, and often the key barrier lies in specific cellular uptake and appropriate intracellular release. 13, 55 Previous work within our group has shown that pDNA condensed with PEI can be fully encapsulated within neutral PEGylated liposomes achieving on average 60% encapsulation yield, where other neutral lipid based vehicles encapsulated 10% or less. 42 It was found that there was no significant statistical difference in encapsulation yield between targeted PEGylated liposomes encapsulating siRNA/PEI complexed at different N:P ratios, while silencing increased with increasing N:P up to N:P 5 6. Others have also observed an increase in siRNA transfection using PEI with increasing N:P up to a certain ratio, followed by a decrease in transfection efficiency. The increase in transfection with increasing N:P ratio was attributed to higher uptake, and the decrease attributed to increasing cytotoxicity at higher N:P ratios. 24, 33, 36, 39 Since binding and internalization of the targeted PEGylated liposomes is largely driven by the targeting peptide as shown before and in Figure   2 , 29 and not by the presence of PEI in the liposomes, this explanation is insufficient in our case. Therefore, we speculated that the increase in siRNA silencing with an optimal N:P ratio of the encapsulated siRNA/ PEI was more likely caused by an optimization of the local buffering capacity within the liposome. [59] [60] [61] was produced from the complexed siRNA following the hydration step of liposome formation. 27 Fluorescence intensity of the standard and of the liposome sample were measured using a Synergy H1 fluorescence microplate reader (Biotek, Winooski, VT). Yield was calculated as final siRNA content after purification compared to initial siRNA content used for encapsulation (100 pmol).
| siRNA/PEI complexation
100 pmol of total siRNA (5% fluorescently labeled siRNA, si18E7- 674 12 ) was complexed using 25 kDa branched PEI (Sigma-Aldrich, St.
Louis, MO). 100 pmol of siRNA was dissolved in 6 mM HEPES buffer, mixed with an equal volume of PEI in 6 mM HEPES at the desired amine to phosphate (N:P) ratio and a final siRNA concentration of 67 nM, was vortexed for 5 s and incubated at room temperature for 20 min. The size of complexed siRNA nanoparticles was measured using a NanoSight LM10 (Malvern Instruments, Malvern, UK) with a 405 nm laser, and zeta potential analysis (Brookhaven Instruments Corporation, Holtsville, NY) was used to measure the surface charge of the particles.
| Isothermal calorimetry (ITC)
siRNA and PEI were prepared in the same buffer to minimize mixing effects. PEI was then injected at 2 lL increments into the siRNA solution using MicroCal Auto-iTC 200 (Malvern Instruments, Malvern, UK)
to measure the power required to maintain a constant chamber temperature. Using the MicroCal Auto-iTC200 software, the resulting power versus time data were integrated to determine heat exchange associated with each injection. The heat of dilution was accounted for by subtracting the heat data obtained from injections of PEI into buffer from the heat data obtained from injecting PEI into an siRNA solution.
The resulting heat curve was fitted to a "one set of sites" binding model, which uses n, the number of binding sites, K, the binding association constant, and DH, the enthalpy of binding, as fitting parameters where all n binding sites have the same K and DH. 38, 40 The data were fitted to the following equations:
where u is the fraction of sites occupied by the siRNA, X ½ is the free siRNA concentration, X t is the bulk siRNA concentration, M t is the bulk PEI concentration, Q is the total heat content of the solution, DQ i ð Þ is the heat released from the ith injection, V o is the volume of the chamber, and dV i is the injection volume at the ith injection. This film was hydrated with 0.75 ml of 2 mM calcein or 1.5 ml of complexed siRNA/PEI at 45 8C for 1.5 hr. These liposomes were extruded 11 times using a manual extruder (Avestin, Ottowa, ON) through 200 nm membranes. For siRNA liposomes, the unencapsulated siRNA was removed with overnight dialysis purification through a 1000 kDa MWCO membrane (Spectrum Laboratories, Rancho Dominguez, CA) and stored at 4-8 8C for up to 4 weeks. 27, 56 Calcein liposomes were purified using a Sepharose CL-4B gel filtration column to remove unencapsulated material and stored at 4-8 8C for up to 4 weeks. Lipid concentration was measured using a phosphorous assay as described elsewhere 73 
| Liposome formation
where C t,ref1 and C t,ref2 are the threshold cycles of the individual reference genes.
HPV-E7 gene silencing was calculated using the following equations. First, the normalized sample threshold cycle, DC t , was determined by subtracting the reference gene threshold cycle (C t,ref ) from the target gene threshold cycle (C t,x ) for each sample:
The difference between treated and untreated threshold cycles, DDC t , was then calculated by subtracting the DC t,untreated of the untreated sample from the DC t,treated of the treated sample:
The fold silencing that was achieved in the treated sample relative to the untreated sample was calculated as follows: were delivered and allowed to incubate for 24 hr at 37 8C and 5% CO 2 .
Cell viability was then measured using a WST-1 Cell Proliferation Reagent (Roche, Indianapolis, IN) following the manufacturer's protocol.
Absorbance was measured using a Synergy H1 microplate reader (Biotek, Winooski, VT). Cell viability was normalized to untreated cells. 
LITERATURE CITED SUPPORTING INFORMATION
Additional Supporting Information can be found the online version of this article at the publisher's website. Table S1 . p-values from ANOVA statistical analysis for Figure 1 showing binding and internalization of fluorescent liposomes with varying peptide concentration and incubation times at 37 8C. 
